Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 8/20 | 0.36 |
| ▸ | FAP | Q12884 | 3/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20630145 | 1.00 | LMNA (0.46) | LMNACA12CA1CA2CA3 | |
| SCHEMBL23959724 | 0.84 | DPP4 (0.33) | LMNACA12CA1CA2CA3 | |
| SCHEMBL29431839 | 0.79 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL30271973 | 0.79 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL28568525 | 0.79 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL31756966 | 0.79 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2026586 | 0.78 | KDM4E (0.46) | LMNACA12CA1CA2CA3 | |
| SCHEMBL22640310 | 0.78 | SIGMAR1 (0.35) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL2557204 | 0.76 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL14301202 | 0.74 | SHBG (0.35) | DPP4FAPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159452-A1 | REGIOSELECTIVE OXIDATION OF HETEROCYCLIC ALPHA-AMINO AMIDES | PHARMAZELL GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230159452-A1 | REGIOSELECTIVE OXIDATION OF HETEROCYCLIC ALPHA-AMINO AMIDES | PHARMAZELL GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230159452-A1 | REGIOSELECTIVE OXIDATION OF HETEROCYCLIC ALPHA-AMINO AMIDES | PHARMAZELL GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| CN-115916746-A | Regioselective oxidation of heterocyclic alpha-aminoamides | 细胞制药有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4139283-A2 | REGIOSELECTIVE OXIDATION OF HETEROCYCLIC ALPHA-AMINO AMIDES | Pharmazell GmbH (DE) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021214278-A2 | REGIOSELECTIVE OXIDATION OF HETEROCYCLIC ALPHA-AMINO AMIDES | PHARMAZELL GMBH (DE) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021214278-A2 | REGIOSELECTIVE OXIDATION OF HETEROCYCLIC ALPHA-AMINO AMIDES | PHARMAZELL GMBH (DE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159452-A1 | REGIOSELECTIVE OXIDATION OF HETEROCYCLIC ALPHA-AMINO AMIDES | CBR1, ABAT, CYP2E1 | LMNA 3211/4885CA12 1361/4885CA1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.